Thanks Tuck, some highlights:
The Company anticipates that GlaxoSmithKline will review its restoration election upon the delivery of Phase 2b trial results. If the Company elects to terminate the agreement and continues or intends to continue any development activities, either alone or in collaboration with a third party, then the Company shall pay an exit fee to GlaxoSmithKline.
According to IMS Health Incorporated, the total United States market for injectable drugs was approximately $20 billion in 2000. Of this market, we believe that drugs with aggregate sales in excess of $7 billion could potentially be delivered using the AERx platform. In addition, most biotech compounds currently under development rely on injection as their primary means of delivery.
We have tested 11 compounds in human clinical trials, two of which are currently in Phase 2 development. We have attracted the attention of some of the world's leading pharmaceutical and biotechnology companies, who have contributed over $75 million for the advancement of our AERx technology. Our most advanced programs include development partnerships with:
- Novo Nordisk, the world leader in insulin products, for the needle-free delivery of insulin for diabetes; and,
- SmithKline Beecham, now GlaxoSmithKline, for the rapid, needle-free delivery of morphine to treat severe pain.
In addition to the above active programs, we have conducted feasibility testing across a broad range of molecules, including an additional four compounds with which we have completed Phase 1 clinical trials that we believe we could pursue in the future. Some of these molecules are listed below:
Chronic Bronchitis and Emphysema drugs
Anti-obesity drugs
Antibodies
Migraine drugs
Gene therapies
Anti-Parkinson's drugs
Asthma drugs
Interleukins
Hematopoetic factors
Interferons
Human growth factors
Antibiotics |
